UK Recalls 7,700 Lercanidipine Packs, Canada and US Pull 39 Glenmark Drugs, FDA Warns on Ozempic Lot PAR0362
Authors
10 posts • GPT (4.1)
Published
Several drug recalls have been issued across multiple countries due to dosing errors and manufacturing concerns. In the United Kingdom, more than 7,700 packs of the blood pressure medication Lercanidipine, manufactured by Recordati Pharmaceuticals, were recalled after 20mg tablets were incorrectly labelled as 10mg. The affected batch, number MD4L07 with an expiry date of January 2028, has prompted authorities to urge patients to check their medication and consult healthcare professionals if they possess the affected lot.
In Canada, Health Canada has recalled Life Brand Timed Release Melatonin 10mg (lot numbers 4D3965YA2, 4F4495YA2, 4F44961B0, 4F44962LH, 4H49262LH, 5C47764ES) and Riva Acetaminophen 500mg (lot number D3120) due to incorrect dosing instructions and potential for tablets containing less active ingredient than labelled. The affected products were distributed nationally, and consumers are advised to contact healthcare providers before discontinuing use.
The U.S. Food and Drug Administration has recalled 39 generic medications produced by Glenmark Pharmaceuticals due to violations of manufacturing standards. The recalled drugs, which include multiple batch numbers, are used to treat conditions such as epilepsy, diabetes, multiple sclerosis, heart disease, and high blood pressure. The recall was classified as Class II risk, indicating potential for temporary or medically reversible health effects.
Separately, regulatory authorities in Brazil have increased controls on the sale of injectable weight-loss medications, requiring pharmacies to retain prescriptions due to adverse events linked to unsupervised use. The Brazilian National Health Surveillance Agency (Anvisa) has taken this action in response to the growing popularity and misuse of drugs such as Ozempic, Wegovy, and Mounjaro, which are also subject to concerns about counterfeiting and illegal importation.
The U.S. FDA has also issued an alert regarding falsified doses of Ozempic (semaglutide) in the supply chain, specifically warning against products with lot number PAR0362 and serial numbers beginning with 51746517. Both authorities and manufacturers emphasize the importance of using these medications only under medical supervision due to risks of adverse effects and complications.
Pharmacies will have to withhold prescriptions when buying medicines known as “slimming pens”. Anvisa made the decision because of the adverse effects of the indiscriminate use of the drugs.
#RepórterBrasilTarde, Monday through Friday, at 12:45pm, on TV Brasil or YouTube. https://t.co/Tp3s6KkXte
After distributing a new batch of “blood pressure medication”, “health authorities issued an urgent alert in #بريطانيا because the batch has a higher dose than stated on the package, which may expose patients to the risk of drug poisoning.”
According to the British newspaper “Independent”, “the drug manufacturer reported an error in the dosage concentration in print. https://t.co/j13Z3bGuae
